🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

As more cancer treatments are developed, doctors need help knowing which therapies will work best. Pangea Biomed's breakthrough platform analyzes a patient's RNA and recommends the best treatment. NFX's omri_drory shares why we led the $7M seed: nfx.com/post/why-nfx-i…

Today, we are celebrating our launch from stealth and $7M in seed funding led by @NfX. Read about our multi-cancer response predictor, set to increase patient benefits from #precisiononcology by 5x: bit.ly/3DWYRll

Can we provide precision oncology to cancer patients without high-cost sequencing just by using their tumor H&E images🔬? We are excited to present the first framework for sequencing-less transcriptome-based precision oncology.⚡️ biorxiv.org/content/10.110…

We are delighted to share that our recent ENLIGHT manuscript is out in MED! cell.com/med/fulltext/S… ENLIGHT is a powerful unsupervised precision oncology tool that can predict response for a wide variety of drugs with minimal data requirements. A 5 minute TL;DR follows

On the heels of our recent Med by Cell Press paper presenting our ENLIGHT treatment matching platform, we are proud to share a case report in @SITCancer about a young patient achieving complete remission from advanced cancer following ENLIGHT-matched therapy. bit.ly/3FpV01c